ethyl benzyl-H-phosphinate | 114425-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl benzyl-H-phosphinate
• 英文别名: benzylphosphinic acid ethyl ester；Ethoxyphosphonoylmethylbenzene
• CAS: 114425-49-9
• 化学式: C₉H₁₃O₂P
• 分子量: 184.175
• InChiKey: XKPLUCXVCCINCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl benzyl-H-phosphinate 在 镍 氨 、 氢气 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 10.0~75.0 ℃ 、10.0 MPa 条件下， 反应 5.0h， 生成 (3-Amino-propyl)-benzyl-phosphinic acid ethyl ester
  参考文献：
  名称：

  Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

  摘要：

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.

  DOI：

  10.1021/jm00017a016
• 作为产物：
  描述：

  benzylphosphinic acid 、 氯甲酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl benzyl-H-phosphinate
  参考文献：
  名称：

  Certain N-substituted-amino-alkane phosphinic acid derivatives having

  摘要：

  具有GABA.sub.B-拮抗性质的化合物，例如具有以下式I的化合物##STR1##其中R.sub.1、R.sub.2和R.sub.3中的一个是氢或脂肪族、环脂族、芳基脂肪族或芳香族基团，另一个是氢或在R.sub.1或R.sub.2的情况下是羟基或在R.sub.1的情况下是卤素或在R.sub.2与R.sub.2'一起是氧代基，其余基团是氢，R.sub.1'是氢或卤素，R.sub.2'是氢、羟基或与R.sub.2一起是氧代基，R.sub.4和R.sub.5是氢或R.sub.4是芳基脂肪族或杂环芳基脂肪族基团，R.sub.5是氢或脂肪族基团，R是至少有2个碳原子的脂肪族、环脂族、环脂族-脂肪族、芳基脂肪族、杂环芳基脂肪族或芳香族基团，当R.sub.1是氢或羟基时，R.sub.2是芳香族基团，且R.sub.1'、R.sub.2'和R.sub.3是氢时，R是甲基，以及它们的药学上可接受的盐，可用作治疗“小发作”型癫痫的药物中的活性成分。该发明还涉及具有式I的新化合物以及其制备方法。

  公开号：

  US05229379A1

文献信息

• DBU-promoted alkylation of alkyl phosphinates and H-phosphonates
  作者：Laurent Gavara、Christelle Petit、Jean-Luc Montchamp

  DOI：10.1016/j.tetlet.2012.07.019

  日期：2012.9

  phosphinates and some H-phosphonate diesters is promoted by the base DBU. Only more reactive alkyl halides react in preparatively useful yields. However, the method provides easy access to important H-phosphinate building blocks, without the need for a protecting group strategy or metal catalysts. The reaction is conveniently conducted at, or below, room temperature. The preparation of methyl-H-phosphinate

  DBU碱促进烷基次膦酸酯和一些H-膦酸酯二酯的烷基化。只有更多的反应性烷基卤化物以制备有用的产率反应。但是，该方法无需重要的保护基策略或金属催化剂即可轻松获得重要的H-次膦酸酯结构单元。该反应方便地在室温或低于室温下进行。甲基的制备ħ -phosphinate酯是特别令人感兴趣的，因为它避免了以往更普遍使用methyldichlorophosphine MePCl的2。
• Modulators of toll-like receptor 7
  申请人：Chong S. Lee

  公开号：US20080008682A1

  公开（公告）日：2008-01-10

  The present application provides for a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.

  本申请提供了一种公式I或II的化合物： 或其药用可接受的盐、溶剂化物和/或酯，包含此类化合物的组合物，包括施用此类化合物的治疗方法和包括与至少一个附加活性剂施用此类化合物的治疗方法。
• Certain N-substituted-amino-alkane phosphinic acid derivatives having
  申请人：Ciba-Geigy Corporation

  公开号：US05229379A1

  公开（公告）日：1993-07-20

  Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.3 are hydrogen, R is methyl, and their pharmaceutically acceptable salts, can be used as active ingredients in medicaments for the treatment of epilepsies of the "petit mal" type. The invention relates also to novel compounds of formula I and processes for the preparation thereof.

  具有GABA.sub.B-拮抗性质的化合物，例如具有以下式I的化合物##STR1##其中R.sub.1、R.sub.2和R.sub.3中的一个是氢或脂肪族、环脂族、芳基脂肪族或芳香族基团，另一个是氢或在R.sub.1或R.sub.2的情况下是羟基或在R.sub.1的情况下是卤素或在R.sub.2与R.sub.2'一起是氧代基，其余基团是氢，R.sub.1'是氢或卤素，R.sub.2'是氢、羟基或与R.sub.2一起是氧代基，R.sub.4和R.sub.5是氢或R.sub.4是芳基脂肪族或杂环芳基脂肪族基团，R.sub.5是氢或脂肪族基团，R是至少有2个碳原子的脂肪族、环脂族、环脂族-脂肪族、芳基脂肪族、杂环芳基脂肪族或芳香族基团，当R.sub.1是氢或羟基时，R.sub.2是芳香族基团，且R.sub.1'、R.sub.2'和R.sub.3是氢时，R是甲基，以及它们的药学上可接受的盐，可用作治疗“小发作”型癫痫的药物中的活性成分。该发明还涉及具有式I的新化合物以及其制备方法。
• Recent advances in phosphorus–carbon bond formation: synthesis of H-phosphinic acid derivatives from hypophosphorous compounds
  作者：Jean-Luc Montchamp

  DOI：10.1016/j.jorganchem.2004.10.005

  日期：2005.5

  This account summarizes the research conducted in our laboratory over the past five years. New methodologies were devised for the formation of P–C bonds with a focus on the reactions of hypophosphorous acid derivatives. Three types of reactions have been developed: palladium-catalyzed cross-coupling, room-temperature radical addition, and palladium-catalyzed addition. Our results are summarized in

  该报告总结了过去五年来我们实验室进行的研究。设计了新的方法来形成P-C键，重点是次磷酸衍生物的反应。已经开发出三种类型的反应：钯催化的交叉偶联，室温自由基加成和钯催化的加成。我们在所有这些领域中总结了我们的结果，其中包括一些我们的最新数据。（1）我们的钯催化交叉偶联已扩展到烷基次膦酸酯与各种芳基，杂芳基甚至烯基亲电试剂的直接偶联。（2）在自由基条件下添加次磷酸钠从烯烃延伸至炔烃。
• Evaluation and Development of Methodologies for the Synthesis of Thiophosphinic Acids
  作者：Karen R. Winters、Jean-Luc Montchamp

  DOI：10.1021/acs.joc.0c01151

  日期：2020.11.20

  thiophosphinic acids are reported. Ultimately, two major approaches were selected: (1) the Stec reaction of phosphorus amides with carbon disulfide; and (2) the one-pot synthesis of thiophosphorus acids from H-phosphinates, an organometallic nucleophile, and quenching with elemental sulfur. An application to the preparation of a potential chiral phosphorus organocatalyst is also reported.

  硫代磷酸R 1 R 2 P（S）OH构成一类重要的有机磷化合物，如果R 1 ≠R 2，则磷原子本质上是手性的。与旨在制备手性硫代磷酸的项目有关，考虑了各种可用的文献方法，但是很少有适合无味试剂的要求。在此，报道了我们关于硫代次膦酸合成的研究结果。最终，选择了两种主要方法：（1）磷酰胺与二硫化碳的Stec反应；（2）由H一锅合成硫代磷酸-次膦酸酯，一种有机金属亲核试剂，并用元素硫淬灭。还报道了在制备潜在的手性磷有机催化剂中的应用。